Barinthus Biotherapeutics
BRNS
BRNS was delisted on the 8th of September, 2026.
12 hedge funds and large institutions have $23.8M invested in Barinthus Biotherapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
1.61% less ownership
Funds ownership: 14.05% → 12.44% (-1.6%)
20% less funds holding
Funds holding: 15 → 12 (-3)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
56% less capital invested
Capital invested by funds: $54.3M → $23.8M (-$30.5M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 2 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
+$8.06K |
| 3 |
JP Morgan Chase
New York
|
+$137 |
| 4 |
Citigroup
New York
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.54M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$462K |
| 3 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$341K |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$108K |
| 5 |
Millennium Management
New York
|
-$18.4K |
BRNS Hedge Fund Activity: Q1 2022 in Review
12 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q1 2022, worth a combined $23.8M — down 56% from $54.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BRNS and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $11.1K. The largest seller was Alphabet Inc, cutting an estimated $1.54M.
- 12 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q1 2022, down from 15 in Q4 2021.
- Funds reported $23.8M of Barinthus Biotherapeutics stock for Q1 2022, down 56% quarter-over-quarter.
- 2 funds opened new Barinthus Biotherapeutics positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Barinthus Biotherapeutics buyer in Q1 2022 was UBS Group, an estimated $11.1K added.
- The largest Barinthus Biotherapeutics seller in Q1 2022 was Alphabet Inc, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2022.